985results about How to "Good physical and chemical stability" patented technology

The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.

The present invention is in the area of administration forms and delivery systems for drugs, vaccines and other biologically active agents. More specifically the invention is related to the preparation of suspensions of colloidal solid lipid particles (SLPs) of predominantly anisometrical shape with the lipid matrix being in a stable polymorphic modification and of suspensions of micron and submicron particles of bioactive agents (PBAs); as well as to the use of such suspensions or the lyophilizates thereof as delivery systems primarily for the parenteral administration of preferably poorly water-soluble bioactive substances, particularly drugs, and to their use in cosmetic, food and agricultural products. SLPs and PBAs are prepared by the following emulsification process: (1) A solid lipid or bioactive agent or a mixture of solid lipids or bioactive agents is melted. (2) Stabilizers are added either to the lipid or bioactive agent and to the aqueous phase or to the aqueous phase only depending on their physicochemical characteristics. Stabilizers may also be added or exchanged after homogenization. (3) Drugs or other bioactive substances to be incorporated into the SLPs may be melted together with the lipids if the physicochemical characteristics of the substance permit or may be dissolved, solubilized or dispersed in the lipid melt before homogenization. (4) The aqueous phase is heated to the temperature of the melt before mixing and may contain for example stabilizers, isotonicity agents, buffering substances, cryoprotectants and/or preservatives. (5) The molten lipid compounds and the bioactive agents are emulsified in an aqueous phase preferably by high-pressure homogenization.

The invention discloses a monodisperse metal atom/graphene composite catalyst and a preparation method and application thereof. The catalyst is formed by loading monodisperse metal atoms on/in graphene, wherein the content of the monodisperse metal atoms is 0.0001wt%-5.0wt%; the content of heteroatom doped graphene is 95wt%-99.9999wt%; and the content of heteroatom in graphene is 0wt%-90wt%. The monodisperse metal atom/graphene composite catalyst is obtained through an electrochemical method, and the preparation method is simple, easy to operate and control, low in cost, high in efficiency, good in quality, high in security and favorable for industrial production. The composite catalyst has the characteristics of high activity and good stability when being applied to electro-catalytic oxygen reduction, and has better comprehensive performance and good application prospects relative to commercial 20wt% of Pt/C.

A novel aluminum antiperspirant active composition of enhanced efficacy is provided. The composition is activated by both heat and acid and characterized by having high HPLC Band III and high HPLC Band IV, prepared by the addition of an acid such as AlCl₃ to (1) the aluminum calcium and/or strontium betaine solutions, where the calcium and/or strontium is derived from a soluble salt such as calcium and/or strontium chloride or nitrate and (2) the aluminum calcium and/or strontium glycine and/or betaine solutions, where calcium and/or strontium is from strongly alkaline calcium/strontium oxide or hydroxide. The novel aluminum compositions derived according to the invention have HPLC Band I of less than 2%; a Band III of at least 20%; a Band III/II ratio of at least about 0.7; and a Band IV of at least 20%.

The present invention provides polypeptides and specific binding agents that modify the activity of an initiator caspase involved in apoptosis, caspase-9. The polypeptides include the third baculoviral IAP repeat (BIR3) of an IAP and form a heterodimer complex with caspase-9. Nucleic acid molecules including expression vectors encoding the polypeptides and variants thereof as well as variants of caspase-9 are provided. Such polypeptide and nucleic acid molecules may be used for modifying apoptosis.

The present invention relates to a method for the displacement of an analyte fluid within a capillary microchannel and to a microfluidic system. In particular, it relates to the field of microfluidics, and especially to microfluidic systems. The method comprises steps which consist in introducing at least one ferrofluid train (3) into the said capillary channel (1), the said ferrofluid train (3) comprising a slug of ferrofluid (5) and, placed against at least one of the two ends of the slug of ferrofluid and in contact with it, a slug of liquid (7) immiscible with both the ferrofluid and the analyte fluid; in introducing the said analyte fluid (9) into the said capillary channel, in proximity to the ferrofluid train and on the side having the slug of liquid (7) immiscible with both the ferrofluid and the analyte fluid; and in controlling the analyte fluid displacement within the said capillary channel by the action of a magnetic field on the ferrofluid train, which field is generated by a magnet system placed on the outside of the said capillary channel.

The present invention provides storage stable dry powder compositions of IL-4R. The powder compositions demonstrate superior chemical and physical stability over their solution counterparts, particularly upon storage under varying conditions of temperature and humidity. Moreover, the powders, as prepared, possess good aerosol properties, which are maintained upon storage.

The invention discloses a composite phase-change energy storage material for microcapsules and a preparation method thereof. The coating of the microcapsule is made of silicon dioxide, and the core of the microcapsule is made of a phase-change energy storage material, wherein the phase-change energy storage material is a paraffin organic solid-liquid phase-change energy storage material. 0.2 to 0.5 wt.% of dispersed emulsifier, 52.5 to 62.5 wt.% of solvent water, 18.75 to 31.5 wt.% of phase-change energy storage material and 15.5 to 18.75 wt.% of inorganic silica source are matched and put into a reactor for stirring for 5 to 8 hours; the mixture is uniformly dispersed and emulsified at the temperature 3 to 8 DEG C higher than that for solid-liquid phase change; hydrochloric acid aqueous solution catalyst with the pH value of 0.93 to 4.07 or sodium hydroxide aqueous solution catalyst with the pH value of 8.0 to 12.0 is added into the emulsion; the reacting solution is naturally cooled to room temperature and precipitation solution is obtained; the precipitate is washed with the combination of water and petroleum ether, wherein the mass percent of the petroleum ether is 30 wt.%; then the precipitate is washed with deionized water and is filtered, and the product is naturally aired. The invention improves the technology of phase-change energy storage and conservation, and has the function of automatic temperature regulation, favorable physical and chemical stability, crack resistance, flame retardancy, wear resistance and high thermal conductivity.

Porous ceramic wall flow filter bodies of unitary or segmented construction wherein the honeycomb channels are alternately plugged with plugging cements incorporating low expansion refractory fillers and permanent inorganic bonding agents, the latter imparting improved plug integrity and plug bonding to the porous ceramic honeycomb channel walls.

A pharmaceutical composition is provided comprising a vehicle that comprises (a) an amphipathic oil that is water dispersible and ethanol insoluble, (b) microcrystalline wax, and (c) a pharmaceutically acceptable non-aqueous carrier; and having an antibacterial substance in an antibacterially effective amount stably dispersed in the vehicle. The composition is suitable for administration by intramammary infusion to a milk producing animal for treatment and/or prevention of mastitis or other diseases of the udder, as well as for otic administration for treatment and/or prevention of an ear infection.

The present invention provides a novel liquid composition suitable for in-situ formation of a depot system to deliver a protein or peptide in a controlled manner. The composition of the present invention comprises: (a) a hydrophobic non-polymeric carrier material; (b) a water miscible biocompatible organic solvent that dissolves the hydrophobic non-polymeric material; (c) a protein or peptide covalently conjugated with one or more formulation performance-enhancing compounds. The present invention also provides a method of manufacturing and use of the composition thereof.

Cell culture media, such as chemically defined cell culture media, are provided, as are methods of using the media for cell growth (i.e., cell culture) and polypeptide (e.g., antibody) production. Compositions comprising polypeptides produced by the methods are also provided.

The delivery of biopharmaceutical and other therapeutic agents parenterally to an animal via a minimally invasive, low pain administration is provided. The agents are delivered to the patient via, e.g., the epidermal, dermal, or subcutaneous layer of the skin in a concentrated form of injectable glucagon that is dissolved in a pharmaceutically acceptable carrier.

The invention provides an anion-deficient non-stoichiometric lithium iron phosphate as an electrode-active material, which is represented by the formula Li_1−xFe(PO₄)_1−y, wherein 0<x≦0.15 and 0<y≦0.05. The invention provides a method for preparing said Li_1−xFe(PO₄)_1−y, which comprises preparing a precursor of lithium iron phosphate; mixing said precursor with water under reaction conditions of 200˜700° C. and 180˜550 bar to produce lithium iron phosphate; and calcining, or granulating and calcining the resultant compound. The invention also provides electrochemical devices employing said Li_1−xFe(PO₄)_1−y, as an electrode-active material.

A container comprising a closure means coated by an inert fluorinated material and containing a liquid pharmaceutical composition. In particular, the container comprises a closure means coated by TEFLON and contains a HSA-free Interferon-β formulation having the following composition: 30 to 100 μg/ml of interferon-β, an isotonicity agent, 0.1 to 2 mg/ml of Poloxamer 188, at least 0.12 mg/ml of L-Methionine and a buffer solution capable of maintaining the pH of the liquid formulation at a value between 3.0 and 4.0.

The present invention relates to aqueous pharmaceutical compositions comprising 2,6-diisopropylphenol (propofol). A composition of the present invention can comprise propofol and two or more excipients as an aqueous mixture. The propofol containing compositions are preferably sterile and are parenterally administered to any animal, including humans. The compositions are also chemically and physically stable over a wide range of environmental conditions.

The present invention relates to topical compositions comprising 5α-reductase inhibitors. The present invention also includes processes for preparation of such topical compositions and methods of using them.

The invention discloses an amphiphilic triblock copolymer with a structural general formula represented as the following. In the formula, when M1 is vinylpyrrolidone and M2 is acrylic acid, M3 is styrene or acrylonitrile or methyl methacrylate; or when M1 is vinylpyrrolidone and M2 is a chemical bond, M3 is styrene or acrylonitrile. m, n, p, q, are all lager than 1. A number-average molecular weight of the copolymer is 30000 to 100000, a glass-transition temperature of the copolymer is 90-180 DEG C, and a decomposition temperature of the copolymer is 180-430 DEG C. The invention also discloses a preparation method of the copolymer, and a polyethersulfone hollow fiber membrane blend-modified by using the amphiphilic triblock copolymer. The amphiphilic triblock copolymer provided by the invention is insoluble in water. When the amphiphilic triblock copolymer is blended with polyethersulfone and is prepared into a polyethersulfone hollow fiber membrane, the amphiphilic triblock copolymeris hard to precipitate. Therefore, the polyethersulfone hollow fiber membrane is provided with permanent hydrophilicity, protein pollution resistance and excellent blood compatibility. The polyethersulfone hollow fiber membrane can be used in the field of blood purification. The preparation method provided by the invention is simple, and is easy to operate. With the method, industrialization is easy to realize.

The present invention relates to the extracting and purifying method of capsanthin pigment with high color number, low spicy degree and no bad taste from ripe chili fruit or peel. The extracting and purifying process includes organic solvent extraction, depression concentration of extractive liquid and separation and purification of the concentrate with macroporous adsorption resin. Measurement in ultraviolet spectrophotometric method shows that the capsanthin pigment of the present invention has color number up to 100 (E449nm) and no spicy taste.

The invention relates to a preparation method of transition metal doped carbon fluorescent quantum dots. According to the method, a metal chelator and transition metal salt are dissolved in an organicphase and water which are incompatible with each other, then, a heating reaction is conducted, concentration and purification are performed after the reaction, and transition metal doped carbon fluorescent quantum dots with different solubility are prepared. The method is convenient to operate, doping of carbon fluorescent quantum dots with metal ions can be realized without harsh reaction conditions or large instruments. The obtained carbon dots have multiple different characteristics according to different types of doping metal ions and different solvents. The prepared carbon dots have great application value in preparation of bio-labeling sensing and medical imaging, photoelectric and light-emitting devices and the like due to these characteristics.

The invention discloses a citric acid loofah sponge preparation method and an application technology. The preparation method provided by the invention is characterized by comprising the following steps of: adding 18-25 wt% of citric acid, 18-25 wt% of saponified loofah sponge and 50-60 wt% of water into a plugged Erlenmeyer flask, putting on a plug, carrying out refluxing at the temperature of 60-70 DEG C for 2-3h with stirring, heating up to the temperature of 110-120 DEG C, reacting for 2-3h, cooling, washing by using deionized water, carrying out pumping filtration until a filtrate is neutral, washing by using a few ethanol, and drying in a baking oven of 75 DEG C to obtain the citric acid loofah sponge. The citric acid loofah sponge has strong adsorption capability, can directly used for the adsorption and elution of various metal ions and organic dyes in a water body, is characterized by high adsorption efficiency, fast adsorption speed, good physical and chemical stability and excellent mechanical stability, and can be used within a wide soda acid range. Simultaneously, the citric acid loofah sponge has regeneration capability and is a natural green adsorbent.

A method is provided for treatment and/or prevention of an infective condition in a fluid-containing organ having a natural exterior orifice, such as the udder of a milk-producing animal or an ear of a subject. The invention also relates to a dispersible pharmaceutical composition suitable for infusion into the organ according to the method of the invention, and to a process for preparing such a composition.

The invention discloses a high-performance oxygen evolution CoO@Co-NC/C composite catalyst as well as preparation method and application thereof. The composite catalyst is prepared by loading Co-coated CoO nano particles and nitrogen doped carbon on a carbon material; the preparation method comprises the following steps: mixing a nitrogen-containing organic small molecule compound, the carbon material and organic acid cobalt salt through a liquid phase, and performing evaporation and drying to obtain mixed powder; putting the mixed powder in a protection atmosphere, and performing two-stage roasting treatment to obtain the CoO@Co-NC/C composite catalyst. The preparation method is simple, low in cost and favorable for industrial production; the prepared CoO@Co-NC/C composite catalyst is applied to water decomposition or the storage and conversion system of renewable resources such as metal-air secondary batteries, and has the characteristics of high activity and high stability; comparedwith a RuO2 commercial catalyst, the CoO@Co-NC/C composite catalyst has better comprehensive performance and shows a good application prospect.

The invention provides an aqueous pharmaceutical composition for administration as an aerosol to the respiratory tract, nose or oropharyngeal region comprising (i) a macrolide having a poor taste and poor chemical stability in aqueous solution; (ii) at least one salt selected from the group consisting of sodium gluconate, sodium aspartate, sodium acetate, sodium lactate, sodium succinate, sodium maleate, magnesium gluconate, magnesium aspartate, magnesium citrate, magnesium acetate, magnesium lactate, magnesium succinate, and magnesium maleate; or mixtures thereof and (iii) a taste-masking agent different from said salt; wherein (a) the concentration of said macrolide in the composition is in the range of about 0.25 wt.-% to about 15 wt.-%; (b) the molar ratio of said macrolide:said salt is in the range from about 1:0.5 to about 1:100; (c) the pH of the composition is in the range of about 3 to 9; and (d) the osmolality of the composition is in the range of about 150 mOsmol/kg to about 1500 mOsmol/kg. The invention further provides a method of generating an aerosol, preferably by means of a nebuliser, which uses such an aqueous pharmaceutical composition. The macrolide may be used alone or in combination with other drugs. The composition is suitable to treat inflammatory disorders and/or infections of the respiratory tract. It has an improved taste and stability.